 |
Hana Biosciences to Present at the 12th Annual BIO CEO & Investor Conference
Feb 1, 2010
|
7.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Feb 1, 2010 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that the executive management team will participate in the 12th Annual BIO CEO & Investor Conference to be held February 8 through Febr...
|
|
Hana Biosciences Appoints Howard Furst, M.D., M.B.A., to Board of Directors
Dec 16, 2009
|
10.6 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Dec 16, 2009 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced the appointment of Howard Furst, M.D., M.B.A., to the Company's Board of Directors. Dr. Furst has over 20 years of experience in the h...
|
|
Hana Biosciences Announces Positive Data From Pivotal rALLy Clinical Trial of Marqibo(R) in Acute Lymphoblastic Leukemia at 51st American Society of Hematology Annual Meeting
Dec 7, 2009
|
12.5 KB |
|
| |
Dec 7, 2009 (GlobeNewswire via COMTEX News Network) --
--36% Overall Response Rate and 21% Complete Remission Rate--
--Median Overall Survival of 7.3 Months in Complete Responders--
SOUTH SAN FRANCISCO, Calif., Dec. 7, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengtheni...
|
|
Hana Biosciences Completes Enrollment in Pivotal Phase 2 rALLy Clinical Trial of Marqibo(R) in Acute Lymphoblastic Leukemia
Dec 2, 2009
|
11.3 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Dec 2, 2009 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it has completed enrollment of its pivotal Phase 2 rALLy clinical trial for Marqibo(R) (vincristine sulfate liposomes injection) f...
|
|
Hana Biosciences to Present Data From Pivotal rALLy Clinical Trial of Marqibo(R) in Acute Lymphoblastic Leukemia
Dec 1, 2009
|
9.7 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Dec 1, 2009 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that top-line data from its pivotal Phase 2 rALLy clinical trial for Marqibo(R) (vincristine sulfate liposomes injection) for the treat...
|
|
Hana Biosciences to Present at the 21st Annual Piper Jaffray Healthcare Conference
Nov 24, 2009
|
7.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Nov 24, 2009 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that Steven R. Deitcher, M.D., President and Chief Executive Officer, will present an overview of the Company at the 21st Annual Piper...
|
|
Hana Biosciences Announces Third Quarter 2009 Results
Nov 13, 2009
|
16.7 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Nov 13, 2009 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (OTCBB:HNAB) announced today financial results for the three and nine months ended September 30, 2009.
"Highlights of the past couple months include completion of a financing with top tier biotechnology investors and intensive preparation for o...
|
|
Hana Biosciences to Present at the 8th Annual BIO Investor Forum
Oct 22, 2009
|
7.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Oct 22, 2009 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that the executive management team will participate in the 8th Annual BIO Investor Forum to be held October 28 through October 29, 200...
|
|
Hana Biosciences Completes $12.4 Million Private Placement
Oct 8, 2009
|
9.4 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Oct 8, 2009 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (OTCBB:HNAB) announced today that it has completed its previously disclosed private placement of units of its securities consisting of shares of common stock and warrants. Hana realized total gross cash proceeds of approximately $12.4 million.
N...
|
|
Hana Biosciences Announces $12.4 Million Private Placement
Oct 8, 2009
|
11.6 KB |
|
| |
Oct 8, 2009 (GlobeNewswire via COMTEX News Network) --
* Financing led by OrbiMed Advisors LLC, Perceptive Life Sciences
Master Fund Ltd., Quogue Capital LLC and Deerfield Management
* Proceeds to be used to advance Hana's lead clinical compound
Marqibo(R)
SOUTH SAN FRANCISCO, Calif., Oct. 8, 2009 (GLOBE NEWSWIRE) -- Hana Bios...
|
|
Hana Biosciences Enters Into Clinical Trial Agreement With the National Cancer Institute for Development of Marqibo(R) in Pediatric Cancer
Sep 30, 2009
|
11.5 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Sep 30, 2009 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (OTCBB:HNAB) today announced that the Company has entered into a Clinical Trial Agreement (CTA) with the Center for Cancer Research (CCR) at the National Cancer Institute (NCI) for the co-development of Marqibo(R) (vincristine sulfate liposomes inj...
|
|
Hana Biosciences Receives NASDAQ Delisting Notification
Sep 8, 2009
|
10.5 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Sep 8, 2009 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (Nasdaq:HNAB) today announced that the Company received a letter from the Staff of The NASDAQ Stock Market indicating that the Company has failed to regain compliance with NASDAQ Marketplace Rule 4310(c)(3), which requires the Company to have a mini...
|
|
Hana Biosciences Announces Second Quarter 2009 Results
Aug 14, 2009
|
15.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Aug 14, 2009 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced financial results for the three and six months ended June 30, 2009.
Three Months Ended June 30, 2009 Financial Results:
The C...
|
|
Hana Biosciences Reaches Patient Enrollment Target for Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
Aug 12, 2009
|
10.6 KB |
|
| |
Aug 12, 2009 (GlobeNewswire via COMTEX News Network) --
56th Subject Enrolled and Dosed
Data Presentation Targeted for 2009 ASH Annual Meeting
NDA Submission Targeted for First Half of 2010
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), today ...
|
|
Hana Biosciences Presents Updated Marqibo Data At the American Society of Clinical Oncology Annual Meeting
Jun 2, 2009
|
11.6 KB |
|
| |
Jun 2, 2009 (GlobeNewswire via COMTEX News Network) --
* 30% CR/CRi Rate in First 33 rALLy Subjects
* rALLy Study Expected to Reach Target Enrollment by Mid-Year
* Encouraging Survival in Metastatic Uveal Melanoma Trial
SOUTH SAN FRANCISCO, Calif., June 2, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutica...
|
|
Hana Biosciences Announces First Quarter 2009 Results
May 15, 2009
|
13.7 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., May 15, 2009 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced financial results for the first quarter ended March 31, 2009.
Net loss was $5.6 million, or $0.17 per share, for the first quarte...
|
|
Hana Biosciences Receives Going Concern Qualification
Apr 9, 2009
|
9.3 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Apr 9, 2009 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences, Inc., (Nasdaq:HNAB), a biopharmaceutical company focused on developing and commercializing new, differentiated cancer therapies designed to improve and enable current standards of care, today announced that its audited financial statements for the ...
|
|
Hana Biosciences Reports Fourth Quarter and Full Year 2008 Results
Mar 31, 2009
|
19.3 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Mar 31, 2009 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences Inc., (Nasdaq:HNAB), a biopharmaceutical company focused on developing and commercializing new, differentiated cancer therapies designed to improve and enable current standards of care, today announced financial results for the fourth quarter and t...
|
|
Hana Biosciences to Report Fourth Quarter and Full Year 2008 Financial Results On March 31, 2009
Mar 18, 2009
|
8.3 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Mar 18, 2009 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (Nasdaq:HNAB) will announce its fourth quarter and full year 2008 results on Tuesday, March 31, 2009, after the close of the financial markets. Following the announcement, Hana Biosciences' management team will host a conference call that day at 5:...
|
|
Hana Biosciences Receives NASDAQ Notice; Will Request Hearing
Mar 11, 2009
|
9.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Mar 11, 2009 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (Nasdaq:HNAB) today announced that the Company received a letter on March 5, 2009 from the Listing Qualifications Staff of The NASDAQ Stock Market LLC (the "Staff Determination") notifying the Company that, based upon its non-compliance with the $2...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter
Shareholder Briefcase
Printed Materials
Email Alerts
Download Library
RSS News Feeds